Anti-Scl-70 (Anti-Topoisomerase I Antibodies)

This test detects antibodies commonly associated with systemic sclerosis (scleroderma), particularly the diffuse form of the disease.

• Diagnostic Value: The presence of Anti-Scl-70 helps confirm a diagnosis of systemic sclerosis when clinical symptoms such as skin thickening or organ involvement are present.
• Prognostic Insight: Anti-Scl-70 antibodies are linked to a higher likelihood of lung involvement (such as interstitial lung disease), making early detection critical for monitoring and treatment.
• Guidance for Care: Identifying this antibody allows physicians to watch more closely for complications and intervene before irreversible organ damage occurs.

Because of its predictive value, the Anti-Scl-70 test supports early detection and tailored management of systemic sclerosis.